We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bribery ‘Blacklist’ is Latest Fallout From Ongoing GSK China Scandal
Bribery ‘Blacklist’ is Latest Fallout From Ongoing GSK China Scandal
Beginning March 1, China’s National Health and Family Planning Commission will publish a blacklist of drugmakers accused by provincial officials of offering bribes to customers.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor